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The metabolic syndrome has been identified as an increasingly important precursor to cardiovascular diseases in many Asian populations.
ur objective was to compare the contribution of component risk factors to the diagnosis of the metabolic syndrome, as defined by the Third
eport of the National Cholesterol Education Program Expert Panel Adult Treatment Panel (NCEP-ATPIII), in the US and selected Asian
opulations. Nationally representative survey data from Hong Kong, Taiwan, Thailand and the US were used. Analyses were restricted to
en and women aged ≥35 years. The age-standardized prevalence of the NCEP-ATPIII defined metabolic syndrome was highest in the US
31% in men, 35% in women), and lowest in Taiwan (11% in men, 12% in women). The component risk factors that defined the presence
f the metabolic syndrome varied between countries. As expected, abnormal waist circumference was considerably more prevalent among
ndividuals with the metabolic syndrome in the US (72% in men, 94% in women) compared with their Asian counterparts, but substantial
ariation was also observed between the Asian populations (13–22% in men, 38–63% in women). Furthermore, the relative contribution of
ther risk factors to the metabolic syndrome was also substantially different between countries. The NCEP-ATPIII definition identifies a
eterogeneous group of individuals with the metabolic syndrome in different populations.
2005 Elsevier Ireland Ltd. All rights reserved.
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The term “metabolic syndrome” describes a clustering of
bnormalities in individuals that confers an increased risk
f developing cardiovascular disease. Working definitions
f this syndrome have recently become available from the
orld Health Organization (WHO) [1] and the US-based
ational Cholesterol Education Program Adult Treatment
anel III (NCEP-ATPIII) [2]. Generic components of the
∗ Corresponding author. Tel.: +61 2 9993 4564; fax: +61 2 9993 4502.
E-mail address: apatel@thegeorgeinstitute.org (A. Patel).
syndrome, common to both definitions, include hypergly-
caemia or impaired glucose tolerance, dyslipidaemia, obe-
sity or abnormal fat distribution and hypertension; the WHO
definition also includes measured insulin resistance and mi-
croalbuminuria. While estimates of the prevalence of the
metabolic syndrome vary according to the definition used
[3,4], studies have confirmed that individuals with a diagno-
sis of metabolic syndrome on the basis of either definition
are at increased risk of diabetes and cardiovascular diseases
[5–9].
021-9150/$ – see front matter © 2005 Elsevier Ireland Ltd. All rights reserved.
oi:10.1016/j.atherosclerosis.2005.04.012
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Using the NCEP-ATPIII definition, it has been estimated
that about one-quarter of US adults aged ≥20 years have
the metabolic syndrome [10]. However, the component risk
factors chosen as well as the cut-points used to define abnor-
mality for each of these risk factors are somewhat arbitrary,
and were selected to be highly sensitive to the presence of
insulin resistance, which is known to vary between ethnic
groups [11]. Given the continuous nature of the associa-
tion between each of the component risk factors and the
risk of cardiovascular disease, the value of fixed threshold
values to define an abnormality can be questioned. How-
ever, even if such threshold values are considered neces-
sary for the practice of clinical or public health medicine,
differences in the distribution of the component risk factors
and their relative contribution to cardiovascular risk between
populations may limit the generalisability of the chosen
cut-points.
Many countries in Asia are undergoing an epidemiological
transition, with chronic non-communicable diseases becom-
ing leading causes of morbidity and mortality. Little is known
about the prevalence of the metabolic syndrome in this region,
and few studies have investigated the implications of applying
metabolic risk factors with cut-points identified in Western
countries to Asian populations. In this report, we compare
the prevalence of the NCEP-ATPIII defined metabolic syn-
























triglycerides were determined using enzymatic methods, and
the PEG 6000 precipitation method was used to measure HDL
cholesterol.
1.2. Taiwan
Data were collected from four nationwide health screen-
ing centres in Taiwan during 1999 [13]. A total of 48,406
subjects with an age and gender distribution similar to the
national population [16] were included in the study. For all
participants, measurements of height, weight, waist and hip
circumferences and blood pressure were obtained using stan-
dard techniques. A venous blood sample was taken after 12 h
of fasting for measurement of serum glucose and lipids, which
were performed using commercially available kits on a Hi-
tachi 7150 Autoanalyzer (Hitachi Ltd., Tokyo, Japan). HDL
cholesterol was measured using the dextran sulphate magne-
sium precipitation method.
1.3. Thailand
Data were collected from a sample of 5305 men and
women aged 35 years and over within representative enu-
merated districts of rural and urban Thailand in 2000 [15].
Physical examination of study participants included stan-opulations.
. Methods
Data from population-based cross-sectional studies in
ong Kong, Taiwan, Thailand and the US were collected
nd analyzed. Each study, described in brief below, was de-
igned to obtain nationally representative data; details of each
tudy have been published elsewhere [12–15]. The laborato-
ies for studies conducted in Hong Kong, Thailand and the
S were standardized according to the criteria of the Cen-
ers for Disease Control—National Heart, Lung and Blood
nstitute Standardization Program. For the study from Tai-
an, the laboratory participates in the College of American
athologists Accreditation Program.
.1. Hong Kong
The Hong Kong cardiovascular risk factor prevalence
tudy was conducted in 1995–1996 and included a repre-
entative sample of 2900 men and women from Hong Kong
sland, Kowloon and the New Territories [14]. Study partic-
pants underwent physical assessment, which included mea-
urement of height, weight, waist and hip circumferences and
lood pressure using standard methods. After 12 h of fast-
ng, serum samples were collected for lipid analyses and a
lucose tolerance test was performed. Biochemical analyses
ere performed using the Hitachi 747 Autoanalyzer (Hitachi
td., Tokyo, Japan). Plasma glucose, total cholesterol anddard assessment of blood pressure, height, weight, waist and
hip circumference. Biochemical analyses of serum glucose
and lipids were performed on venous samples obtained after
an 8 h overnight fast, using the Dimension RxLHM clinical
chemistry system (Dade Behring Inc., Newark, USA). Serum
glucose, total cholesterol and triglycerides were measured us-
ing enzymatic methods, with the DADE Accelerator selective
detergent method for HDL cholesterol determination.
1.4. United States
The Third National Health and Nutrition Examination Sur-
vey (NHANES III) was designed to obtain nationally rep-
resentative information on the health and nutritional status
of the civilian, non-institutionalized US population through
interviews and direct physical examinations [12]. The sur-
vey was conducted between 1988 and 1994, and included
33,199 men and women aged ≥17 years. After interview,
participants were invited to undergo a standard physical as-
sessment, which included measurement of blood pressure,
height, weight, and waist circumference. Blood samples were
obtained after a period of fasting of at least 8 h, with bio-
chemical analyses performed using a Hitachi 704 Autoana-
lyzer (Boehringer Mannheim Diagnostics, Indianapolis, IN).
Enzymatic methods were used to measure total cholesterol
and triglycerides, while a precipitation method (heparin man-
ganese) was used for HDL cholesterol assay. Serum glucose
was also analyzed by enzymatic method, using the Cobas
Mira Chemistry System (Roche Diagnostics Systems, Inc.,
Montclair, NJ).
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1.5. Deﬁnition of metabolic syndrome
As described in the NCEP-ATPIII report [2], individuals
within each study were classified as having abnormal levels of
risk factors according to the following criteria: (1) blood pres-
sure: abnormal if systolic blood pressure≥130 mmHg and/or
diastolic blood pressure≥85 mmHg; (2) serum triglycerides:
abnormal if ≥150 mg/dl (1.69 mmol/L); (3) serum HDL
cholesterol: abnormal if <40 mg/dL (1.04 mmol/L) in men,
or <50 mg/dl (1.29 mmol/L) in women; (4) waist circumfer-
ence: abnormal if >102 cm in men, or >88 cm in women;
and (5) fasting blood glucose: abnormal if ≥110 mg/dL
(6.1 mmol/L). The metabolic syndrome was defined by the
presence of at least three of these five abnormalities.
1.6. Statistical analysis
For each study, analyses were restricted to adults aged
35 years or above (as the study conducted in Thailand was
limited to this population) and to those individuals with com-
plete data available for each of the risk factors included in the
definition of the metabolic syndrome. Where required to en-
sure estimates were representative of the populations [14,15],
the STATA 8.0 statistical software package (StataCorp., Col-
lege Station, TX, USA) was used to apply appropriate na-























































































































































































































































































































































































































































































































































































































































































































































.with standard errors) of mean levels of risk factors and pro-
ortions with metabolic abnormalities were calculated sep-
rately for men and women within each study population.
irect age-standardization [17] of estimates was based on
he latest WHO World Standard Population [18], and age-
tandardized proportions are presented, although the results
ere similar without adjustment. Comparisons of the pro-
ortion of individuals with risk factor abnormalities between
opulations were performed using χ2-test, while differences
n mean values of continuous variables were examined us-
ng t-test, with adjustment for multiple comparisons using a
onferroni correction.
. Results
The number and characteristics of the participants in-
luded in the analysis from each study are shown in Table 1.
he mean age of the US population was greater than that of
ach Asian population. Among the component risk factors of
he metabolic syndrome, mean values of blood pressure and
aist circumference were similar among the Asian countries,
nd more favourable than in the US. Lower HDL choles-
erol values in Hong Kong and Thailand were observed in
he presence of lower mean total cholesterol levels—mean to-
al/HDL cholesterol ratios for each population are also shown
n Table 1. Mean triglyceride levels were greatest in Thailand.
In all populations, the majority of men and women aged 35
ears or over had abnormal levels of at least one component
isk factor of the metabolic syndrome (Fig. 1). The prevalence
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Fig. 1. Age-standardized prevalence of 0, 1, 2, 3, 4 and 5 NCEP-defined
metabolic abnormalities among men and women aged ≥35 years in Hong
Kong, Taiwan, Thailand and the US. The proportion of individuals with the
metabolic syndrome (≥3 NCEP-defined abnormalities) is shown. Estimates
have been age-standardised to the World Standard Population 2000 [18].
of the NCEP-ATPIII defined metabolic syndrome (abnormal
levels of≥3 risk factors) was lowest in Taiwan and highest in
the US for both men (11% versus 31%, p < 0.001) and women
(12% versus 35%, p < 0.001). Of the Asian populations, the
prevalence of the metabolic syndrome was greatest in Thai-
land (19% in men, 27% in women). In each population, the
metabolic syndrome was more prevalent among women than
men (all p < 0.01).
A comparison of the age-standardized prevalence of
abnormal levels of the component risk factors among indi-
viduals with the NCEP-ATPIII defined metabolic syndrome
between populations is shown in Table 2. The most strik-
ing differences observed are in the proportions of individuals
with abnormal waist circumference—in the US population
with the metabolic syndrome these proportions were 72%
for men and 93% for women. The corresponding values for
the Asian countries ranged from 14 to 22 and 38 to 64%. Con-
versely, the Asian populations with the metabolic syndrome
were more likely to have abnormal HDL levels than their US
counterparts. Individuals with the metabolic syndrome from
Taiwan and Thailand had a higher prevalence of abnormal
triglyceride levels than in the other countries studied (partic-
ularly among men). The proportion of individuals with the
metabolic syndrome classified as having an abnormal fasting
glucose was lowest in the US, and greatest in Taiwan. There












Proportion (S.E.) with each NCEP-defined metabolic abnormality, among adults ag
Study Blood pressurea Triglyceridesb HDL ch
Male
Hong Kong 85 (3.2) 81 (3.1) 88 (2.7)
Taiwan 57 (1.1) 94 (0.5) 89 (0.6)
Thailand 78 (2.0) 92 (1.3) 79 (2.0)
US 82 (1.1) 84 (1.0) 73 (1.2)
Female
Hong Kong 80 (3.9) 65 (4.2) 95 (1.7)
Taiwan 54 (1.4) 88 (0.8) 91 (0.6)
Thailand 57 (1.7) 79 (1.5) 93 (0.9)
US 70 (1.2) 71 (1.2) 78 (1.0)
Estimates age-standardized to the WHO World Standard Population [18].
a Systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmH
b Serum triglycerides ≥150 mg/dL (1.69 mmol/L).
c Serum high density lipoprotein (HDL) cholesterol <40 mg/dL (1.04 mmol/L) in
d Waist circumference >102 cm in men and >88 cm in women.
e Fasting blood glucose ≥110 mg/dL (6.1 mmol/L).ndividuals with NCEP-ATPIII defined high blood pressure,
anging from about one-half of men and women in Taiwan,
o more than 80% of their counterparts in Thailand.
Despite using the same NCEP-ATPIII defined thresh-
ld values in each population, there was some variation in
he unadjusted mean values for each of the component risk
actors among individuals with and without NCEP-defined
etabolic syndrome between populations (Table 3). This was
articularly true for systolic blood pressure, HDL cholesterol
nd waist circumference, suggesting differences in the risk
rofile of individuals both with and without the syndrome,
ed ≥35 years with the metabolic syndrome
olesterolc Waist circumferenced Fasting blood glucosee
22 (3.4) 56 (4.2)
14 (0.8) 67 (1.1)
20 (2.0) 58 (2.4)
72 (1.2) 39 (1.3)
51 (4.4) 51 (4.4)
38 (1.4) 62 (1.4)
64 (1.6) 46 (1.8)
94 (0.5) 37 (1.2)
g.
men and <50 mg/dL (1.29 mmol/L) in women.
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Table 3












MS No MSa MS No MSa MS No MSa MS No MSa MS No MSa
Male
Hong Kong (n = 1155) 139 (1.9) 120 (0.9) 2.6 (0.16) 1.3 (0.03) 0.90 (0.01) 1.18 (0.01) 93 (0.8) 82 (0.3) 6.8 (0.18) 5.3 (0.04)
Taiwan (n = 23,380) 137 (0.4) 124 (0.1) 2.5 (0.02) 1.5 (0.01) 0.91 (0.00) 1.20 (0.00) 91 (0.2) 83 (0.1) 7.1 (0.06) 5.5 (0.01)
Thailand (n = 2453) 134 (1.3) 117 (1.0) 3.4 (0.16) 1.8 (0.07) 0.95 (0.02) 1.13 (0.03) 90 (1.2) 79 (0.8) 7.0 (0.12) 5.3 (0.07)
US (n = 4626) 142 (0.5) 131 (0.3) 2.8 (0.04) 1.4 (0.02) 0.99 (0.01) 1.31 (0.01) 107 (0.3) 94 (0.2) 6.8 (0.08) 5.4 (0.03)
Female
Hong Kong (n = 1100) 147 (1.7) 116 (1.3) 2.2 (0.11) 1.0 (0.02) 1.02 (0.01) 1.38 (0.01) 88 (0.6) 74 (0.3) 7.4 (0.37) 5.1 (0.02)
Taiwan (n = 25,026) 144 (0.4) 121 (0.1) 2.3 (0.02) 1.2 (0.00) 1.10 (0.00) 1.48 (0.00) 85 (0.2) 73 (0.1) 7.1 (0.06) 5.3 (0.01)
Thailand (n = 2646) 131 (1.0) 115 (0.7) 2.5 (0.08) 1.4 (0.06) 1.04 (0.01) 1.25 (0.03) 90 (0.9) 78 (0.6) 6.5 (0.17) 5.2 (0.05)
US (n = 5092) 142 (0.5) 126 (0.4) 2.4 (0.03) 1.2 (0.01) 1.19 (0.01) 1.56 (0.01) 102 (0.3) 89 (0.2) 6.9 (0.08) 5.1 (0.02)
a For individuals without MS—p < 0.05 (after correction for multiple comparisons) for all between-population sex-specific comparisons of risk factors, except
triglycerides—Taiwan vs. US in women; fasting blood glucose—Hong Kong vs. Thailand in men, and Hong Kong vs. US in women.
in different countries. This is exemplified by differences
in mean systolic blood pressure between those with and
without the metabolic syndrome, ranging from 11 mmHg
(US) to 19 mmHg (Hong Kong) among men, and 16 mmHg
(US) to 31 mmHg (Hong Kong) among women. Similarly,
differences in other risk factor levels between those with
and without the metabolic syndrome varied substantially
between populations, including for triglycerides (e.g. 1.0
and 1.6 mmol/L for Taiwanese and Thai men, respectively),
HDL cholesterol (e.g. 0.18 mmol/L for Thai men versus
0.32 mmol/L among US males), and fasting blood glucose
(e.g. 1.3 mmol/L among Thai women versus 2.3 mmol/L for
women from Hong Kong).
Across all age and sex strata examined, the prevalence
of NCEP-ATPIII defined metabolic syndrome was greater
in the US population compared with the Asian populations
(Fig. 2). The prevalence of the metabolic syndrome generally
increased with age, this observation being least consistent
among men in Thailand. With aging, the increasing preva-
lence of the metabolic syndrome was observed to a greater
extent among women than men across all populations studied.
3. Discussion













with and without the metabolic syndrome among women in
the US was 16 mmHg, while the corresponding difference
among Thai women was 31 mmHg. Based on blood pressure
alone, and using estimates of the association in blood pres-
sure and coronary heart disease from epidemiological studies
[19–21] (∼20% higher risk for each 10 mmHg higher level of
systolic blood pressure), women with NCEP-ATP III defined
“hypertension” in the US would have ∼35% higher risk of
coronary heart disease compared with the remainder of the
population; the corresponding figure for Thai women would
be ∼75%.
The HDL cholesterol cut-point used in the NCEP-ATPIII
definition also highlights the difficulty of establishing a sin-
gle threshold value that is meaningful across populations. In
contrast to the general pattern of more unfavourable cardio-
vascular risk factor levels in the US population compared to
the Asian populations, HDL cholesterol levels were higher
in the US. However, whether this higher level of HDL in the
US population really indicates or confers a lower cardiovas-
cular risk when compared against the Asian populations is
uncertain, because total cholesterol levels in the US popula-
tion are also higher. Likewise, the validity of elevated triglyc-
eride levels as an indicator of increased cardiovascular risk
in the Thai population is also uncertain—high mean triglyc-
eride values have been a consistent observation amongst adult











eCEP-ATPIII defined metabolic syndrome is lower among
dults in Hong Kong, Taiwan and Thailand, compared with
dults in the United States. However, application of NCEP-
TPIII defined threshold values defined strikingly heteroge-
ous groups of individuals with the metabolic syndrome, not
nly when comparisons were made between Asian and US
opulations, but also for comparisons between Asian popu-
ations. The use of a single definition identifies individuals
ith the metabolic syndrome who, in different populations,
re likely to have a variable risk of developing cardiovascular
isease relative to the remainder of the population. For exam-
le, the difference in systolic blood pressure between thoseroximately 70% of the adult population [22–25]. The basis
or this lipid profile has not been established, but may in part
elate to the very high carbohydrate, low fat diets consumed
n many regions.
There was marked variation between the populations in
he proportion of subjects with waist circumference above
he NCEP-ATPIII defined threshold. This reflects the large
ifferences in body mass index and waist circumference be-
ween Asian and Western populations. As defined by uni-
ersal WHO criteria, therefore, the prevalence of abdominal
besity is much lower in Asian countries than in the US. How-
ver, there is evidence that the relationship between body fat
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Fig. 2. The prevalence of the metabolic syndrome according to the NCEP criteria, amongst adults aged ≥35 years in Hong Kong, Taiwan, Thailand and the
US.
and disease varies between ethnic groups, with some Asian
populations experiencing higher levels of disease at lower
levels of body mass index than Western populations [26,27].
In one cross-sectional study from Singapore, receiver opera-
tor characteristic analysis indicated that waist circumference
cut-points that best predicted the clustering of other metabolic
abnormalities were substantially lower than those used in the
NCEP-ATPIII definition [28]. Thus, it has been suggested
that the definition of both overall obesity and abdominal obe-
sity in Asian populations should be based on lower waist cir-
cumference cut-points, perhaps 80 and 90 cm for women and
men, respectively [28,29]. Indeed, the recent International
Atherosclerosis Society recommendations suggest three dif-
ferent waist circumference cut-points for Caucasian popula-
tions, Asia-Pacific populations, and the Japanese [30]. Use
of different thresholds would significantly affect estimates
of the prevalence of the metabolic syndrome, as has been
shown in Hong Kong Chinese and in Singaporean popula-
tions [28,31]. However, the current analyses indicate sub-
stantial variation in the proportion of individuals with the
NCEP-defined metabolic syndrome fulfilling the definition
of obesity between countries in Asia, thus the appropriate-
ness of a single cut-point within these populations remains
questionable.
There are some limitations to these analyses. Data col-
lection was not entirely contemporaneous, and while each
laboratory employed rigorous quality control procedures, the
exact methods used for lipid and glucose assay differed be-
tween studies. Methods for HDL assay, while all based on
precipitation, did vary between studies, thus small differences
in HDL cholesterol and total/HDL cholesterol ratio between
populations should be treated with caution. However, differ-
ences in assay are unlikely to account for the large variation
in prevalence for most risk factors observed between popu-
lations, or alter the conclusions of these analyses.
Another potential limitation is that we did not define
those on blood pressure-lowering treatment as having NCEP-
defined hypertension regardless of blood pressure levels, and
therefore differences in the proportion of individuals treated
between populations may confound the results. However,
even in the US, where the highest treatment rates are likely to
be observed, other data indicate that only ∼7% of the adult
population has treated hypertension with blood pressure lev-
els less than 140/90 mmHg [32]. Furthermore, any such “mis-
classification” is likely to increase the contrast between the
US and the Asian populations, in relation to blood pressure
differences among those with and without the metabolic syn-
drome.
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The difficulties and uncertainty about the value of estab-
lishing a categorical, single, and broadly generalisable clin-
ical definition for the metabolic syndrome does not detract
from the importance of identifying patients with clustering
of risk factors. These individuals with multiple “metabolic”
abnormalities are clearly at increased risk of developing vas-
cular disease. Such recognition is highly consistent with the
emerging paradigm in cardiovascular prevention of evalu-
ating and treating the absolute risk of an individual, rather
than simply measuring and managing individual risk factors.
However, “counting” risk factors (using threshold values to
define abnormality) has been abandoned in favour of continu-
ous risk tools (e.g. Framingham risk charts) to estimate an in-
dividual’s risk of developing cardiovascular disease based on
conventional risk factors [33]. Application of such methods to
“metabolic” risk factors and further research directed toward
the identification of locally relevant indicators of long-term
risk may be particularly useful in many low- and middle-
income countries of the Asia Pacific region, where efficient
targeting of limited health care resources toward those with
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